KR20100102092A - 아자시티딘 유사체 및 이들의 용도 - Google Patents

아자시티딘 유사체 및 이들의 용도 Download PDF

Info

Publication number
KR20100102092A
KR20100102092A KR1020107008902A KR20107008902A KR20100102092A KR 20100102092 A KR20100102092 A KR 20100102092A KR 1020107008902 A KR1020107008902 A KR 1020107008902A KR 20107008902 A KR20107008902 A KR 20107008902A KR 20100102092 A KR20100102092 A KR 20100102092A
Authority
KR
South Korea
Prior art keywords
formula
compound
integer
subject
aza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020107008902A
Other languages
English (en)
Korean (ko)
Inventor
루이스 실버만
제임스 홀란드
마리트 릴란드 샌드볼드
핀 미렌
올레 헨릭 에릭슨
Original Assignee
마운트 시나이 스쿨 오브 메디신
클라비스 파마 에이에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마운트 시나이 스쿨 오브 메디신, 클라비스 파마 에이에스에이 filed Critical 마운트 시나이 스쿨 오브 메디신
Publication of KR20100102092A publication Critical patent/KR20100102092A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
KR1020107008902A 2007-09-26 2008-09-25 아자시티딘 유사체 및 이들의 용도 Withdrawn KR20100102092A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97543707P 2007-09-26 2007-09-26
US60/975,437 2007-09-26

Publications (1)

Publication Number Publication Date
KR20100102092A true KR20100102092A (ko) 2010-09-20

Family

ID=40511851

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020107008902A Withdrawn KR20100102092A (ko) 2007-09-26 2008-09-25 아자시티딘 유사체 및 이들의 용도
KR1020107007252A Withdrawn KR20100072230A (ko) 2007-09-26 2008-09-25 아자시티딘 유사체 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020107007252A Withdrawn KR20100072230A (ko) 2007-09-26 2008-09-25 아자시티딘 유사체 및 이의 용도

Country Status (15)

Country Link
US (2) US8399420B2 (OSRAM)
EP (2) EP2205073A4 (OSRAM)
JP (2) JP2010540556A (OSRAM)
KR (2) KR20100102092A (OSRAM)
CN (2) CN101877964A (OSRAM)
AU (2) AU2008304380A1 (OSRAM)
BR (2) BRPI0817269A2 (OSRAM)
CA (2) CA2700207A1 (OSRAM)
IL (1) IL204690A0 (OSRAM)
MX (2) MX2010003002A (OSRAM)
NZ (2) NZ583923A (OSRAM)
RU (1) RU2488591C2 (OSRAM)
UA (2) UA99836C2 (OSRAM)
WO (2) WO2009042767A1 (OSRAM)
ZA (1) ZA201001660B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497292B2 (en) 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
KR20100102092A (ko) 2007-09-26 2010-09-20 마운트 시나이 스쿨 오브 메디신 아자시티딘 유사체 및 이들의 용도
PT3782611T (pt) 2008-05-15 2022-11-18 Celgene Corp Formulações orais de análogos da citidina e métodos de utilização dos mesmos
EP2321302B1 (en) 2008-08-01 2014-10-29 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
EP2424845A4 (en) * 2009-04-27 2014-03-05 Reddys Lab Ltd Dr PREPARATION OF DECITABIN
US9393255B2 (en) 2011-01-31 2016-07-19 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
WO2012142411A1 (en) * 2011-04-15 2012-10-18 Clavis Pharma Asa Systems and methods for detecting hent1 expression in hematological disorders
CN104168884A (zh) 2011-11-01 2014-11-26 细胞基因公司 使用胞苷类似物的口服制剂治疗癌症的方法
MX358303B (es) 2012-02-24 2018-08-14 Signal Pharm Llc Uso de 7-(6-(2-hidroxipropan-2il) piridin-3-il)-1-((1r,4r)4-metoxi ciclohexil)-3, 4-dihidropirazin-[2,3-b] pirazin-2(1h)-ona o una sal, estereoisómero o tautómero aceptable farmaceuticamente del mismo, en combinación con una cantidad efectiva de erlotinib o azacitidina para preparar un composición farmacéutica en el tratamiento de cáncer de pulmón de cédula no pequeña, avanzado.
US9493500B2 (en) 2012-07-19 2016-11-15 Richard Daifuku Fluorinated pyrimidine analogs and methods of use thereof
NZ631082A (en) * 2013-04-17 2017-06-30 Signal Pharm Llc Methods for treating cancer using tor kinase inhibitor combination therapy
WO2015195786A2 (en) 2014-06-17 2015-12-23 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
SMT202100592T1 (it) * 2014-12-26 2021-11-12 Univ Emory Derivati antivirali della n4-idrossicitidina
WO2017090264A1 (ja) 2015-11-27 2017-06-01 大原薬品工業株式会社 ５－アザシチジン又は其の２'－デオキシ体の５'位ジベンジル燐酸エステル
EP3960182B1 (en) 2015-12-03 2025-03-19 EpiDestiny, Inc. Compositions containing decitabine, 5-azacytidine and tetrahydrouridine and uses thereof
ES2963046T3 (es) 2017-03-20 2024-03-25 Vaccinex Inc Tratamiento del cáncer con un anticuerpo contra la semaforina-4d combinado con un agente modulador epigenético
MX2019015731A (es) 2017-06-22 2020-08-03 Celgene Corp Tratamiento de carcinoma hepatocelular caracterizado por infeccion por virus de hepatitis b.
EP3781584A4 (en) * 2018-04-19 2022-05-11 Southern Research Institute 4'-THIO-NUCLEOTIDE AND NUCLEOSIDE PRODRUGS FOR THE TREATMENT OF CANCER
WO2022035852A1 (en) * 2020-08-10 2022-02-17 The Johns Hopkins University Decitabine analogs for immunological and oncological therapy

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE612384A (fr) * 1961-01-10 1962-05-02 Spofa Vereinigte Pharma Werke Procédé de préparation des 1-glycosyle-6-aza-uraciles
GB1050899A (OSRAM) * 1963-12-22
DE2012888C3 (de) * 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
DE2122991C2 (de) * 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
US3984396A (en) * 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US3998807A (en) * 1972-03-03 1976-12-21 Syntex (U.S.A.) Inc. Arabinofuranosyl cytosines and methods of making
US4172889A (en) * 1976-03-29 1979-10-30 The Upjohn Company Method of treating rheumatoid arthritis
US4405611A (en) * 1980-06-27 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services Bisulfite stabilization of 5-azacytidine
DE3100478A1 (de) 1981-01-09 1982-08-12 Dr. Thilo & Co GmbH, 8021 Sauerlach 5'ester von pyrimidinnucleosiden mit antiviraler wirksamkeit, verfahren zur herstellung und daraus hergestellte arzneimittel
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
DE3737456A1 (de) 1986-11-04 1988-05-19 Fuji Photo Film Co Ltd Laserlichtquelle
CS264454B1 (cs) 1987-08-28 1989-08-14 Piskala Alois 2'-Deoxy-5,6-dihydro-5-azacytidin a způsob jeho výroby
CS264456B1 (cs) 1987-08-28 1989-08-14 Piskala Alois Způsob výroby 5,6-dihydro-S-azacytidinu
US5994392A (en) * 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US4984396A (en) * 1988-08-29 1991-01-15 Uragami Fukashi Cleaning device
DE3834435A1 (de) * 1988-10-10 1990-06-13 Basf Ag Verbrueckte, wasserloesliche copolymerisate, verfahren zu ihrer herstellung und ihre verwendung
US5216142A (en) 1989-04-17 1993-06-01 Efamol Holdings Plc Anti-virals
JP2559917B2 (ja) * 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
DE4026265A1 (de) 1990-08-20 1992-02-27 Boehringer Mannheim Gmbh Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
JP3101321B2 (ja) * 1991-02-19 2000-10-23 富士通株式会社 酸素を含んだアイソレーション領域を有する半導体装置およびその製造方法
US5385912A (en) * 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
DK0599968T3 (da) * 1991-08-14 2000-04-17 Procter & Gamble Pharma Oxazolidinonderivater, der er egnede som antiarytmi- og antifibrilleringsmidler
GB2260319B (en) * 1991-10-07 1995-12-06 Norsk Hydro As Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
GB9515279D0 (en) * 1995-07-25 1995-09-20 Norsk Hydro As Improved therapeutic agents
GB9307043D0 (en) * 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
DE19505168A1 (de) * 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
WO1997005143A1 (en) 1995-07-25 1997-02-13 Asahi Kasei Kogyo Kabushiki Kaisha Novel group 4 transition metal compounds
BR9610070A (pt) * 1995-08-08 1999-07-27 Univ Jefferson Sequência de ácido nucleico polipetídeos compostos antifibrótico e processo para tratar distúrbios ou doenças relacionadas com fibrose para usar a sequência de dna e para produzir c-proteinase recombinante
CA2229414A1 (en) 1995-09-15 1997-03-20 Anadys Pharmaceuticals, Inc. Arylhydrazone derivatives useful as antibacterial agents
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
ES2151277T3 (es) * 1996-05-22 2000-12-16 Protarga Inc Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
JPH10158192A (ja) * 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
GB2321455A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
SK283879B6 (sk) * 1997-01-24 2004-04-06 Conpharma As Deriváty gemcitabínu, spôsob ich prípravy, ich použitie a farmaceutický prostriedok s ich obsahom
ES2194320T3 (es) * 1997-06-03 2003-11-16 Itochu Techno Chem Inc Sustancias naturales antivirales o antitumorales y uso de las mismas.
JP2001524486A (ja) 1997-11-25 2001-12-04 プロタルガ，インコーポレーテッド ヌクレオシド類似成分組成物およびその使用
WO1999041231A1 (en) * 1998-02-17 1999-08-19 Ono Pharmaceutical Co., Ltd. Amidino derivatives and drugs containing the same as the active ingredient
WO2000076979A1 (de) 1999-06-09 2000-12-21 Bayer Aktiengesellschaft Pyridincarboxamide und ihre verwendung als pflanzenschutzmittel
WO2001018013A1 (en) 1999-09-08 2001-03-15 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
KR100480320B1 (ko) * 1999-10-15 2005-04-07 에프. 호프만-라 로슈 아게 벤조디아제핀 유도체
US6670341B1 (en) * 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
NZ533094A (en) 2001-11-21 2006-01-27 Heidelberg Pharma Gmbh Phospholipid derivatives of nucleosides as antitumoral medicaments
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
CA2499036A1 (en) 2002-09-24 2004-04-08 Koronis Pharmaceuticals, Incorporated 1,3,5-triazines for treatment of viral diseases
US7038038B2 (en) * 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6943249B2 (en) * 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
WO2004101593A1 (ja) 2003-05-16 2004-11-25 Kissei Pharmaceutical Co., Ltd. ５’−修飾ヌクレオシド誘導体及びその医薬用途
US7244732B2 (en) * 2003-06-20 2007-07-17 Koronis Pharmaceuticals, Incorporated Prodrugs of heteroaryl compounds
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
JP2007537999A (ja) 2003-12-19 2007-12-27 コローニス ファーマシューティカルズ インコーポレイテッド 変異原性複素環
US20080188527A1 (en) 2003-12-23 2008-08-07 Cashman John R Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer
AU2005210039B2 (en) 2004-02-04 2010-09-02 Neurosearch A/S Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands
US7192781B2 (en) * 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
US8158770B2 (en) 2004-05-06 2012-04-17 University Of Rochester Content dependent inhibitors of cytidine deaminases and uses thereof
GB0419416D0 (en) 2004-09-01 2004-10-06 Inst Of Ex Botany Ascr 4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof
US20060063735A1 (en) * 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
WO2006048771A1 (en) 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
EP1937283A2 (en) 2005-09-19 2008-07-02 Celator Pharmaceuticals, Inc. Combination formulations of cytidine analogs and platinum agents
JP5114202B2 (ja) 2005-09-27 2013-01-09 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するスルホンアミド誘導体
NO324263B1 (no) 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
US20070225248A1 (en) * 2006-03-21 2007-09-27 Clavis Pharma As Oral dosage forms of gemcitabine derivatives
KR20100102092A (ko) 2007-09-26 2010-09-20 마운트 시나이 스쿨 오브 메디신 아자시티딘 유사체 및 이들의 용도

Also Published As

Publication number Publication date
JP2010540556A (ja) 2010-12-24
NZ583923A (en) 2012-05-25
CN101815437A (zh) 2010-08-25
AU2008304380A1 (en) 2009-04-02
WO2009042766A1 (en) 2009-04-02
EP2197274A1 (en) 2010-06-23
UA99308C2 (ru) 2012-08-10
US20090209482A1 (en) 2009-08-20
MX2010003261A (es) 2010-08-18
UA99836C2 (en) 2012-10-10
BRPI0817234A2 (pt) 2014-09-30
RU2010116274A (ru) 2011-11-10
US8399420B2 (en) 2013-03-19
JP2010540555A (ja) 2010-12-24
WO2009042766A9 (en) 2009-05-28
US8158605B2 (en) 2012-04-17
EP2205073A1 (en) 2010-07-14
RU2010116154A (ru) 2011-11-10
CA2700207A1 (en) 2009-04-02
AU2008304381A1 (en) 2009-04-02
EP2197274A4 (en) 2013-03-06
IL204690A0 (en) 2010-11-30
RU2488591C2 (ru) 2013-07-27
EP2205073A4 (en) 2013-03-06
US20090209477A1 (en) 2009-08-20
KR20100072230A (ko) 2010-06-30
CA2700267A1 (en) 2009-04-02
NZ583824A (en) 2012-06-29
ZA201001660B (en) 2011-05-25
MX2010003002A (es) 2010-07-05
CN101877964A (zh) 2010-11-03
WO2009042767A1 (en) 2009-04-02
BRPI0817269A2 (pt) 2014-10-07

Similar Documents

Publication Publication Date Title
KR20100102092A (ko) 아자시티딘 유사체 및 이들의 용도
RU2168995C2 (ru) Фармацевтические композиции, соединения, способы получения соединений
JP7558963B2 (ja) 修飾されたマイクロｒｎａ及びがんの処置におけるその使用
US10500224B2 (en) Mutual prodrug comprising short chain fatty acids and zebularine or 1'-cyano-cytarabine for cancer treatment
CN114685414A (zh) 用于治疗用途的糖脂及其药物组合物
RU2487883C2 (ru) Аналоги азацитидина и их применение
CN105229020B (zh) 氟化嘧啶类似物及其使用方法
JP2019506434A (ja) ２’，２’−ジフルオロ−５−アザ−２’−デオキシシチジンまたはそれらのプロドラッグを有するｔｐ５３野生型腫瘍の治療方法
US9493500B2 (en) Fluorinated pyrimidine analogs and methods of use thereof
TW202539625A (zh) 包括９－順式視黃酸及單醣之綴合化合物
EP2854864B1 (en) Compositions comprising oligomers of gemcitabine for use in therapy
CA2816554A1 (en) Use of 2',5'-oligoadenylate derivative compounds

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100423

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid